Obesity and IBS as likely associated comorbidities


About this study

This study will evaluate obesity as a comorbidity in a population of patients with irritable bowel syndrome (IBS), and assess this cohort for vitamin D-deficiency. It will also determine whether alterations in the fecal microbiome and metaproteome, associated with vitamin D deficiency or other factors, underpin obesity-IBS comorbidity.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Twenty-four (24) IBS-D patients who meet ROME III enrollment criteria and 8 age-matched healthy control patients (6 female, 2 male)

Exclusion Criteria:

  • Diagnosed but untreated Celiac.
  • Diagnosed but untreated Microscopic colitis.
  • Diagnosed but Untreated Hypothyroidism.
  • Inflammatory bowel disease.
  • Fructose intolerance.
  • Gastric bypass.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Lucinda Harris, M.D.

Open for enrollment

Contact information:

Jennifer Hill

(480) 301-4750


More information


Publications are currently not available